drugset / Trial / NCT01220297
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A continuation study of sirolimus and mycophenolate mofetil (MMF) for graft-vs-host disease (GvHD) prophylaxis for patients undergoing matched related allogeneic hematopoietic stem cell transplantation (HSCT) for acute and chronic leukemia, myelodysplastic syndrome (MDS), high risk non-Hodgkin lymphoma (NHL), or Hodgkin lymphoma (HL)
Timeline
- Start
- 2006-08
- Primary completion
- 2010-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mycophenolate Mofetil | Small molecule | 15 mg/kg | Intravenous |
| Subject | Sirolimus | Small molecule | 1 mg/m2 | Oral |
| Subject | Sirolimus | Small molecule | 4 mg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 60 mg/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 100 mg/kg | Intravenous |
| Background | Etoposide | Small molecule | 60 mg/kg | Intravenous |
| Background | carmustine | Small molecule | 15 mg/kg | Intravenous |
| Background | carmustine | Small molecule | 550 mg/m2 | Intravenous |